otamixaban
Sanofi admits $285m failure
June 4, 2013Research and Development, Sales and Marketing Sanofi, its benzamide iniparib, otamixaban
Sanofi has consigned two investigational drugs to the corporate dustbin, preferring a $285 million dent in its coffers to continuing …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
